Curi RMB Capital LLC Has $21.09 Million Position in Stryker Corporation $SYK

Key Points

• Curi RMB Capital LLC reduced its stake in Stryker Corporation by 5.3% during the first quarter, holding 56,544 shares valued at $21,093,000.
• Insider Viju Menon and Director Ronda E. Stryker sold shares, with Menon selling 500 shares and Stryker selling 200,000 shares, reflecting decreases in their ownership.
• Stryker achieved $6.02 billion in revenue and reported an EPS of $3.13 for its last quarter, exceeding analysts' expectations, and has set FY 2025 guidance at 13.400-13.600 EPS.

Curi RMB Capital LLC lessened its position in Stryker Corporation (NYSE:SYK - Free Report) by 5.3% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 56,544 shares of the medical technology company's stock after selling 3,141 shares during the period. Curi RMB Capital LLC's holdings in Stryker were worth $21,093,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Capital A Wealth Management LLC bought a new position in shares of Stryker in the 4th quarter valued at about $26,000. Goodman Advisory Group LLC bought a new position in shares of Stryker in the 1st quarter valued at about $32,000. City Holding Co. grew its position in shares of Stryker by 528.6% in the 1st quarter. City Holding Co. now owns 88 shares of the medical technology company's stock valued at $33,000 after acquiring an additional 74 shares during the period. Smallwood Wealth Investment Management LLC bought a new position in shares of Stryker in the 1st quarter valued at about $40,000. Finally, IMA Advisory Services Inc. bought a new position in shares of Stryker in the 1st quarter valued at about $46,000. Institutional investors own 77.09% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have recently commented on SYK. BTIG Research reissued a "buy" rating on shares of Stryker in a research report on Monday, July 14th. Wall Street Zen raised shares of Stryker from a "hold" rating to a "buy" rating in a research report on Friday, July 18th. Truist Financial set a $415.00 target price on shares of Stryker and gave the stock a "hold" rating in a report on Monday, August 4th. Citigroup reaffirmed a "buy" rating and set a $455.00 target price (up previously from $443.00) on shares of Stryker in a report on Thursday, May 22nd. Finally, Wells Fargo & Company lifted their target price on shares of Stryker from $435.00 to $445.00 and gave the stock an "overweight" rating in a report on Friday, August 1st. Fifteen investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $430.10.

Stryker Stock Performance

Stryker stock traded down $2.32 during midday trading on Friday, hitting $392.02. The company's stock had a trading volume of 1,094,061 shares, compared to its average volume of 1,050,233. Stryker Corporation has a 1-year low of $329.16 and a 1-year high of $406.19. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.78 and a quick ratio of 1.06. The company has a 50-day moving average price of $389.52 and a two-hundred day moving average price of $379.56. The company has a market cap of $149.87 billion, a price-to-earnings ratio of 51.92, a PEG ratio of 2.85 and a beta of 0.93.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.13 earnings per share for the quarter, topping the consensus estimate of $3.07 by $0.06. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The business had revenue of $6.02 billion during the quarter, compared to analysts' expectations of $5.92 billion. During the same quarter in the previous year, the company earned $2.81 EPS. The business's revenue was up 11.1% on a year-over-year basis. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. As a group, sell-side analysts predict that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be paid a $0.84 dividend. The ex-dividend date is Tuesday, September 30th. This represents a $3.36 annualized dividend and a yield of 0.9%. Stryker's payout ratio is 44.50%.

Insider Activity

In other news, Director Ronda E. Stryker sold 200,000 shares of the business's stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total value of $75,290,000.00. Following the completion of the transaction, the director directly owned 3,222,108 shares in the company, valued at approximately $1,212,962,556.60. The trade was a 5.84% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Viju Menon sold 500 shares of the business's stock in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $390.61, for a total transaction of $195,305.00. Following the completion of the transaction, the insider owned 12,511 shares of the company's stock, valued at $4,886,921.71. The trade was a 3.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is owned by insiders.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.